At the news
? NEUTRALIMPACT 4/10 CLUSTER filed May 7, 2026 at 16:31 ET
A cluster of insider sales at United Therapeutics (UTHR) totaling $1.72M occurred within 8 days of a Q1 2026 earnings release showing a 2% YoY revenue decline and a 15% drop in net income. The sales are predominantly by the CEO (Martine Rothblatt) and CFO (James Edgemond), largely tied to option exercises, and represent only ~0.007% of the company's $24.6B market cap, a trivial amount. The earnings miss and competitive pressure on Nebulized Tyvaso are the more material signals, but the insider sales themselves are routine and non-informative.
- Total insider sales of $1.72M represent ~0.007% of UTHR's $24.6B market cap, far below the 0.1% materiality threshold.
- CEO Rothblatt sold ~$2.2M worth of shares across multiple days, all tied to option exercises (non-cash acquisition of shares).
- CFO Edgemond sold ~$734K, also tied to option exercises.
- Q1 2026 revenues fell 2% YoY to $781.5M; net income dropped 15% to $274.9M.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access